Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Above Fifty Day Moving Average - What's Next?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.36 and traded as high as $3.04. Aldeyra Therapeutics shares last traded at $3.02, with a volume of 1,155,240 shares trading hands.

Wall Street Analyst Weigh In

ALDX has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday, May 19th. Wall Street Zen upgraded Aldeyra Therapeutics to a "sell" rating in a report on Wednesday, May 21st. Finally, BTIG Research decreased their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Monday, April 7th.

Aldeyra Therapeutics Stock Performance

The stock has a market cap of $180.89 million, a PE ratio of -3.11 and a beta of 0.68. The company has a fifty day moving average price of $2.36 and a 200 day moving average price of $4.36. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. Analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the firm's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the sale, the insider now directly owns 5,875,851 shares of the company's stock, valued at $8,343,708.42. This trade represents a 36.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.60% of the stock is owned by insiders.

Institutional Trading of Aldeyra Therapeutics

Several large investors have recently modified their holdings of the business. Strs Ohio bought a new stake in shares of Aldeyra Therapeutics in the first quarter worth about $440,000. Acadian Asset Management LLC boosted its position in Aldeyra Therapeutics by 7,402.7% during the 1st quarter. Acadian Asset Management LLC now owns 95,960 shares of the biotechnology company's stock valued at $551,000 after acquiring an additional 94,681 shares in the last quarter. Jane Street Group LLC bought a new stake in Aldeyra Therapeutics during the 1st quarter valued at approximately $1,024,000. Jacobs Levy Equity Management Inc. bought a new stake in Aldeyra Therapeutics during the 1st quarter valued at approximately $218,000. Finally, AQR Capital Management LLC boosted its position in Aldeyra Therapeutics by 456.3% during the 1st quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company's stock valued at $2,257,000 after acquiring an additional 321,992 shares in the last quarter. 59.71% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.